FDA Warns Companies Over Illegal Marketing Of Botox

February 14, 2026

In November 2025, the U.S. Food and Drug Administration issued 18 warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox. The FDA is aware of adverse events associated with unapproved and misbranded botulinum toxin products[...]

Continue Reading

GAO Report: FDA Falling Short Regarding Medical Device Recalls

February 8, 2026

The United States Government Accountability Office (GAO) issued a report to the United States Congress in December 2025 entitled “HHS and FDA Should Address Limitations in Oversight of Recall Process” in which it stated: From fiscal years 2020 to 2024, FDA oversaw the recall of 3,934 med[...]

Continue Reading